Skip to Content
Merck
  • Neutrophil extracellular traps promote differentiation and function of fibroblasts.

Neutrophil extracellular traps promote differentiation and function of fibroblasts.

The Journal of pathology (2014-04-18)
Akrivi Chrysanthopoulou, Ioannis Mitroulis, Eirini Apostolidou, Stella Arelaki, Dimitrios Mikroulis, Theocharis Konstantinidis, Efthimios Sivridis, Maria Koffa, Alexandra Giatromanolaki, Dimitrios T Boumpas, Konstantinos Ritis, Konstantinos Kambas
ABSTRACT

Neutrophil activation by inflammatory stimuli and the release of extracellular chromatin structures (neutrophil extracellular traps - NETs) have been implicated in inflammatory disorders. Herein, we demonstrate that NETs released by neutrophils treated either with fibrosis-related agents, such as cigarette smoke, magnesium silicate, bleomycin, or with generic NET inducers, such as phorbol 12-myristate 13-acetate, induced activation of lung fibroblasts (LFs) and differentiation into myofibroblast (MF) phenotype. Interestingly, the aforementioned agents or IL-17 (a primary initiator of inflammation/fibrosis) had no direct effect on LF activation and differentiation. MFs treated with NETs demonstrated increased connective tissue growth factor expression, collagen production, and proliferation/migration. These fibrotic effects were significantly decreased after degradation of NETs with DNase1, heparin or myeloperoxidase inhibitor, indicating the key role of NET-derived components in LF differentiation and function. Furthermore, IL-17 was expressed in NETs and promoted the fibrotic activity of differentiated LFs but not their differentiation, suggesting that priming by DNA and histones is essential for IL-17-driven fibrosis. Additionally, autophagy was identified as the orchestrator of NET formation, as shown by inhibition studies using bafilomycin A1 or wortmannin. The above findings were further supported by the detection of NETs in close proximity to alpha-smooth muscle actin (α-SMA)-expressing fibroblasts in biopsies from patients with fibrotic interstitial lung disease or from skin scar tissue. Together, these data suggest that both autophagy and NETs are involved not only in inflammation but also in the ensuing fibrosis and thus may represent potential therapeutic targets in human fibrotic diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interleukin-17A human, ≥98% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
IL-17 human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
Propidium iodide solution
Sigma-Aldrich
Phorbol 12-myristate 13-acetate, synthetic, ≥98.0% (TLC)
Sigma-Aldrich
Propidium iodide, ≥94% (HPLC)
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Interleukin-17A human, IL-17A, recombinant, expressed in HEK 293 cells, HumanKine®, suitable for cell culture
Sigma-Aldrich
Phorbol 12-myristate 13-acetate, ≥99% (TLC), film or powder
Sigma-Aldrich
PMA, for use in molecular biology applications, ≥99% (HPLC)